Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Schmitz, F.-J.
Right arrow Articles by C. Fluit, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schmitz, F.-J.
Right arrow Articles by C. Fluit, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1999) 44, 847-849
© 1999 The British Society for Antimicrobial Chemotherapy

Correspondence

Cross-resistance analyses and molecular typing of Staphylococcus aureus and Streptococcus spp. isolates resistant to quinupristin/dalfopristin

J Antimicrob Chemother 1999; 44: 847-849

Franz-Josef Schmitza,b,*, Ralf Sadurskia, Andre Stattfelda, Angela Kraya, Jan Verhoefb, A. C. Fluitb and the SENTRY Participants Group

a Institute for Medical Microbiology and Virology, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany b Eijkman-Winkler Institute for Medical Microbiology, Utrecht University, Utrecht, The Netherlands

Sir,

During the past two decades Gram-positive bacteria, predominantly staphylococci and streptococci, have re-emerged as important pathogens. Staphylococci, in particular, have demonstrated a remarkable propensity for acquiring mechanisms of resistance to every new antimicrobial to become available and for spreading among patients, institutions and communities. More recently, there have also been increasing concerns about ß-lactam resistance in Streptococcus pneumoniae and other streptococci. Clearly, there is a pressing need to identify novel compounds that can be used as therapy for patients with infections caused by these organisms.1

Quinupristin/dalfopristin, a combination of two streptogramins, is one such agent. It has been shown to have excellent activity in vitro against a broad range of staphylococci . . . [Full Text of this Article]

Acknowledgments

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
N. A. Ahmed, F. C. Petersen, and A. A. Scheie
AI-2/LuxS Is Involved in Increased Biofilm Formation by Streptococcus intermedius in the Presence of Antibiotics
Antimicrob. Agents Chemother., October 1, 2009; 53(10): 4258 - 4263.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
S. Gander, K. Hayward, and R. Finch
An investigation of the antimicrobial effects of linezolid on bacterial biofilms utilizing an in vitro pharmacokinetic model
J. Antimicrob. Chemother., February 1, 2002; 49(2): 301 - 308.
[Abstract] [Full Text] [PDF]